VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
EQ
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
EQEquillium, Inc.
$2.77$267M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

EQ logoEquillium, Inc.(EQ)Earnings, Financials & Key Ratios

EQ•NASDAQ
$2.77
Price updated Jul 6, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryImmunology and Inflammation Therapies
AboutEquillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Show more
  • Revenue$0-100.0%
  • EBITDA-$24M-189.2%
  • Net Income-$22M-177.6%
  • EPS (Diluted)-0.39-69.6%
  • ROE-93.99%-142.6%

EQ Price & Volume

Equillium, Inc. (EQ) stock price & volume — 10-year historical chart

Loading chart...

Clinical Development Focus Drives Persistent Cash Burn

Investment Thesis • Updated 2026Q1

VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding shortfall

Key Thesis Takeaways

  • Equillium operates as a high-risk, clinical-stage biotechnology firm currently devoid of commercial revenue, placing the entire investment thesis on the successful regulatory validation of its pipeline.
  • The company faces significant financial headwinds, evidenced by an accumulated deficit of $216.2 million and a reliance on external financing to sustain R&D outlays that have reached as high as $10.8 million in a single quarter.
  • Investors should monitor the company's ability to secure non-dilutive capital or strategic partnerships, as the current cash position of $30.3 million suggests a limited runway for ongoing operations.

Verdict Logic

the company's lack of commercial revenue and the rapid erosion of cash reserves to $30.3 million as of 2025Q4 present significant dilution risks for equity holders.

EQ Growth Metrics

Equillium, Inc. (EQ) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-
3 Years-
TTM-100%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-36.23%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM2.87%

Return on Capital

10 Years-52.26%
5 Years-65.81%
3 Years-59.71%
Last Year-98.06%

EQ Recent Earnings

Equillium, Inc. (EQ) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 5/12 qtrs (83%)
Q2 2026Latest
May 13, 2026
Metric
Actual
Est
EPS
$0.06-50.0%
$0.04
Rev
—
—
Q2 2026
Mar 25, 2026
Metric
Actual
Est
EPS
$0.04+42.9%
$0.07
Rev
—
—
Q4 2025
Nov 13, 2025
Metric
Actual
Est
EPS
$0.06+57.1%
$0.14
Rev
—
—
Q3 2025
Aug 14, 2025
Metric
Actual
Est
EPS
$0.16-14.3%
$0.14
Rev
—
—
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 13, 2026
$0.06vs $0.04-50.0%
—
Q2 2026Mar 25, 2026
$0.04vs $0.07+42.9%
—
Q4 2025Nov 13, 2025
$0.06vs $0.14+57.1%
—
Q3 2025Aug 14, 2025
$0.16vs $0.14-14.3%
—
Based on last 12 quarters of dataView full earnings history →

Latest EQ News

Recent stock market news and headlines for Equillium, Inc. (EQ)

Accesswire·Jun 18, 2026
EQ Works Expands Multi-Year Partnership with Leading Canadian Publisher to Include SaaS License for ClearLake

Three-year renewal follows early campaign results that delivered up to 40% increases in average order value and nearly double the conversion rates using ClearLake TORONTO, ON / ACCESS Newswire / June 18, 2026 / EQ Inc. (TSXV:EQ.V) ("EQ Works" or the "Company"), a leader in AI and data-driven software and solutions that empowers brands to better understand, acquire, and retain their most valuable customers, today announced a three-year renewal and expansion of its partnership with a leading Canadian publisher, including the adoption of a SaaS license for its proprietary ClearLake platform. Under the expanded agreement, the publisher's internal teams will gain direct access to ClearLake to independently conduct advanced customer, competitor, and market research using EQ Works' proprietary data and analytics.

Peers Comparison

Key metrics vs top competitors for Equillium, Inc. (EQ)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
EQ logoEQEquillium, Inc.Current
$2.77$266.69M-7.10-100%—-93.99%—
IMVT logoIMVTImmunovant, Inc.
$38.60$7.92B-13.94——-68.16%—
ARQT logoARQTArcutis Biotherapeutics, Inc.
$26.07$3.26B-200.5491.34%-0.57%-1.41%—
CABA logoCABACabaletta Bio, Inc.
$3.01$490.79M-1.84——-131.58%—
KMDA logoKMDAKamada Ltd.
$7.49$432.07M20.2412.12%11.21%7.73%—
RAPT logoRAPTRAPT Therapeutics, Inc.
$58.01$295.54M-2.28——-61.81%—

Compare EQ vs Peers

Equillium, Inc. (EQ) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs IMVT

Most directly comparable listed peer for EQ.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare EQ against a more recognizable public peer.

Peer Set

Compare Top 5

vs IMVT, ARQT, CABA, KMDA

EQ SEC Filings & Documents

Equillium, Inc. (EQ) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 13, 2026·SEC

Material company update

Mar 25, 2026·SEC

Material company update

Mar 13, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 25, 2026·SEC

FY 2025

Mar 27, 2025·SEC

FY 2024

Mar 25, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 13, 2026·SEC

FY 2025

Nov 13, 2025·SEC

FY 2025

Aug 14, 2025·SEC

Get notified when EQ posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

EQ Frequently Asked Questions

Equillium, Inc. (EQ) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
How fast is Equillium, Inc. growing?

Equillium, Inc. (EQ) saw revenue decline by 100.0% over the past year.

Is EQ profitable?

Equillium, Inc. (EQ) reported a net loss of $19.1M for fiscal year 2025.

Dividend & Returns
What is EQ's return on equity?

Equillium, Inc. (EQ) has a return on equity (ROE) of -94.0%. Negative ROE indicates the company is unprofitable.

What is Equillium, Inc.'s free cash flow?

Equillium, Inc. (EQ) had negative free cash flow of $18.9M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in EQ back in 2017?

Total return calculator · dividends reinvested · 9+ years of data

See returns →